ProCE Banner Activity

Immune Checkpoint Inhibitors: A Game Changer in GI Malignancies

Clinical Thought
With the first immunotherapy agent approved for use in colorectal cancer, how is this going to change your practice?

Released: June 21, 2017

Expiration: June 20, 2018

No longer available for credit.

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Tanios Bekaii-Saab, MD, has disclosed that he has received consulting fees from Amgen, Coherus, and Glenmark; consulting fees (paid to his institution) from Amgen, Bayer, Bristol-Myers Squibb, Celgene, Genentech, Ipsen, Merrimack, and Roche; and has participated in data and safety monitoring boards for Armo, Exelixis, Merck, and Sillajen.